Aims and scope
Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical, epidemiological and translational research providing an insight into the association between chronic infections and cancer.
The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular:
• HPV and anogenital cancers, as well as head and neck cancers;
• EBV and Burkitt lymphoma;
• HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases;
• HHV8 and Kaposi sarcoma;
• HTLV and leukemia;
• Cancers in Low- and Middle-income countries.
The link between infection and cancer has become well established over the past 50 years, and infection-associated cancer contribute up to 16% of cancers in developed countries and 33% in less developed countries.
Preventive vaccines have been developed for only two cancer-causing viruses, highlighting both the opportunity to prevent infection-associated cancers by vaccination and the gaps that remain before vaccines can be developed for other cancer-causing agents. These gaps are due to incomplete understanding of the basic biology, natural history, epidemiology of many of the pathogens that cause cancer, the mechanisms they exploit to cause cancer, and how to interrupt progression to cancer in human populations. Early diagnosis or identification of lesions at high risk of progression represent the current most critical research area of the field supported by recent advances in genomics and proteomics technologies.
Moreover “omics” is contributing to and accelerating the discovery not only of novel pathogens, but of genetic predisposition as the genetic make-up of organisms and individuals is unraveled. The hunt for molecular signatures of cancer causation, early cancer, or cancer Achilles heels promises new ways to practice precision medicine and public health. The explosion of knowledge in tumor genomics, tumor biology, targeted therapies, gene-environment interactions, immunology and immunotherapy needs a space for robust and vigorous debate.
Infectious Agents and Cancer covers all these areas of biomedical research and any other topics pertinent to the development of preventive strategies, innovative diagnostic and biomolecular methodologies, promising therapeutic strategies for chronic infections and cancer. Immunotherapeutic strategies will include: profiling and activation of dendritic cells; reactivation of the immune system; breaking immune tolerance; modulation of the immune system by cytokines and drug delivery systems.
All articles published by Infectious Agents and Cancer are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Infectious Agents and Cancer you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Infectious Agents and Cancer therefore levies an article-processing charge of £1370.00/$2145.00/€1745.00 for each article accepted for publication.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BioMed Central provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
All articles published in Infectious Agents and Cancer are included in:
- PubMed Central
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Infectious Agents and Cancer operates a single-blind peer-review system where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
After an initial screening for general suitability by the Managing Editor, submissions are sent to at least two experts in the field who are asked to evaluate whether the manuscript is scientifically sound and coherent and whether the manuscript should be accepted, rejected or revised. The Editors will reach a decision based on these reports and, where necessary, consult with members of the Editorial Board.
The journal aims to provide authors with a first decision (accepted/rejected/revisions needed) within six weeks.
All manuscripts submitted to Infectious Agents and Cancer should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Infectious Agents and Cancer
Articles in Infectious Agents and Cancer should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Infect Agents Cancer [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Infect Agents Cancer 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Infectious Agents and Cancer
Infectious Agents and Cancer's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Infectious Agents and Cancer offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Infectious Agents and Cancer gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Infectious Agents and Cancer are included in article alerts and regular email updates. Some may be highlighted on Infectious Agents and Cancer’s pages and on the BioMed Central homepage.
In addition, articles published in Infectious Agents and Cancer may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Infectious Agents and Cancer. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Infectious Agents and Cancer you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.
Infectious Agents and Cancer is affiliated with the African Organisation for Research & Training In Cancer (AORTIC)
- Editorial Board
- Editors' Profile
- Sign up for article alerts and news from this journal
2016 Journal Metrics
34 days from submission to first decision
12 days from acceptance to publication
740.0 Usage Factor
Social Media Impact